In summary, the in vitro and in vivo preclinical data provided herein for CD70 expressing tumor cells of renal cell carcinoma origin supports the further development of a CD70-TTC for this indication. This evidence concerns the gene CD70 and hereditary clear cell renal cell carcinoma.